Ovarian Cancer Treatment in India 2026: Surgery, Chemotherapy and Targeted Therapy Options for African Women
Ovarian Cancer Treatment in India 2026: Surgery, Chemotherapy and Targeted Therapy for African Women
April is Ovarian Cancer Awareness Month — a time to highlight one of the most challenging gynaecological malignancies, often diagnosed at advanced stage because early symptoms are subtle and non-specific. Bloating, pelvic discomfort, early satiety: the signs are easily attributed to other conditions until the cancer is well-established.
For women across Africa diagnosed with ovarian cancer, the treatment journey presents difficult challenges. Gynaecological oncology as a subspecialty is limited in most African countries. The complex surgical skills needed for optimal cytoreductive surgery, the molecular targeted therapies that have transformed outcomes in the last decade, and the PARP inhibitors now considered standard maintenance — these are often simply unavailable.
India has built comprehensive gynaecological oncology programmes that provide all of this, at costs that are accessible compared to Western alternatives.
Understanding Ovarian Cancer: Types and Staging
Ovarian cancer is not a single disease. The most common type — epithelial ovarian cancer — accounts for approximately 90% of cases. Within this category:
- High-grade serous carcinoma (HGSC): The most common and aggressive subtype, strongly associated with BRCA1/2 mutations
- Low-grade serous carcinoma: Slower growing, less chemotherapy-sensitive
- Endometrioid: Often diagnosed at earlier stage, better prognosis
- Clear cell carcinoma: More common in Asian women, relatively chemotherapy-resistant
- Mucinous: Less common, often diagnosed early
Other ovarian malignancies include germ cell tumours (more common in younger women), sex cord-stromal tumours, and borderline tumours (low malignant potential).
Staging (FIGO classification):
- Stage I: Confined to ovaries
- Stage II: Extending to pelvis
- Stage III: Spread to peritoneum or retroperitoneal lymph nodes
- Stage IV: Distant metastases (liver parenchyma, lungs, other organs)
Approximately 75% of ovarian cancer cases are diagnosed at Stage III or IV, which is why outcomes have historically been poor globally. India's treatment approach addresses this advanced-stage reality directly.
Treatment Options Available in India
Primary Cytoreductive Surgery (Debulking Surgery)
The cornerstone of ovarian cancer treatment. The goal is to remove all visible tumour, leaving no residual disease (R0 resection). This requires a skilled gynaecological oncologist — surgery may involve removing both ovaries and tubes, the uterus, omentum, peritoneal surfaces, parts of the bowel, appendix, and diaphragm.
India's gynaecological oncologists at Apollo, Tata Memorial, Medanta, and other centres perform these ultra-radical procedures regularly. The surgical skill required is demanding, and outcomes are volume-dependent — higher-volume centres achieve better R0 resection rates.
HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
HIPEC involves bathing the abdominal cavity with heated chemotherapy immediately after cytoreductive surgery. It delivers high local drug concentrations to microscopic peritoneal disease. Available at select Indian oncology centres. Cost adds approximately $5,000-8,000 to the cytoreductive surgery package.
Neoadjuvant Chemotherapy
For patients where primary debulking is not immediately feasible due to disease extent, 3-4 cycles of chemotherapy first shrink the tumour, followed by interval debulking surgery. This approach avoids excessively complex primary surgery and is appropriate for many Stage IIIC/IV cases.
Standard Chemotherapy (First-Line)
The established first-line for epithelial ovarian cancer is platinum-based doublet chemotherapy:
- Carboplatin + Paclitaxel every 3 weeks for 6 cycles
Intraperitoneal chemotherapy and dose-dense weekly regimens are offered at specialist centres.
Cost of chemotherapy in India: A full 6-cycle carboplatin/paclitaxel course costs $3,000-6,000 at Indian hospitals, versus $30,000-60,000 in the USA.
Targeted Therapy: Bevacizumab
Bevacizumab (Avastin), an anti-VEGF antibody, is added to chemotherapy for high-risk advanced disease. The bevacizumab biosimilar is available in India at $400-600 per cycle — a fraction of the $8,000+ per cycle cost in the USA.
PARP Inhibitors: The Game-Changer
PARP inhibitors have transformed maintenance therapy for ovarian cancer, particularly in BRCA-mutated cases:
- Olaparib (Lynparza): Generic olaparib is now available in India at approximately $800-1,200/month, versus $15,000+/month in the USA
- Niraparib (Zejula): Available in India at similar pricing
- Rucaparib: Less commonly used but available
For BRCA1/2-mutated patients completing first-line platinum-based chemotherapy, PARP inhibitor maintenance reduces recurrence risk by 70%+ and is now standard of care. India's availability of affordable generic PARP inhibitors makes this standard accessible.
BRCA Testing
BRCA1/2 genetic testing in India costs $150-300 — accessible, fast (results in 2-3 weeks), and essential for treatment planning. All patients with epithelial ovarian cancer should be tested. Positive results also have implications for daughters and sisters.
Top Gynaecological Oncology Centres in India
Tata Memorial Hospital (Mumbai)
India's premier dedicated cancer institution. Government-funded with subsidised treatment costs. Highest volume gynaecological oncology programme in India. Some waiting time for surgery.
Apollo Cancer Centres (Delhi, Chennai, Hyderabad)
Comprehensive gynaecological oncology with dedicated tumour board review. Strong in robotic gynaecological surgery. International patient programme well-established.
Fortis Memorial Research Institute (Gurgaon)
Strong gynaecological oncology unit with experienced surgeons and modern chemotherapy suites.
Medanta – The Medicity (Gurgaon)
Tumour board approach with multidisciplinary team including radiation, medical, and surgical oncologists.
AIIMS (Delhi)
Government institution with highly experienced faculty. Significant waiting times but exceptional clinical expertise. Best for complex or recurrent cases.
Treatment Cost Summary
| Treatment Component | India Cost | USA Cost |
|---|---|---|
| Primary cytoreductive surgery | $8,000–15,000 | $80,000–150,000 |
| 6 cycles carboplatin/paclitaxel | $3,000–6,000 | $30,000–60,000 |
| Bevacizumab maintenance (6 months) | $5,000–10,000 | $80,000–150,000 |
| Olaparib maintenance (per year) | $10,000–15,000 | $150,000–200,000 |
| BRCA genetic testing | $150–300 | $1,500–3,000 |
For comparison, view how cancer treatment costs in India compare to USA and UK.
Fertility Preservation for Young Patients
For women of reproductive age with ovarian cancer who wish to preserve fertility, India's oncology centres coordinate with IVF units for fertility preservation before chemotherapy begins.
Options include:
- Embryo cryopreservation (requires a partner or donor sperm)
- Oocyte cryopreservation
- Ovarian tissue cryopreservation (experimental but available at some centres)
Read our fertility preservation guide for cancer patients for detailed information.
Getting Started with Arodya
Ovarian cancer diagnosis is frightening. The steps that follow require clarity and good guidance. Begin your inquiry at /intake with your diagnosis details, staging, and any treatment already received. Our clinical team includes oncology specialists who will review your case and recommend the most appropriate centre and oncologist.
We coordinate second opinions remotely before you travel — an Indian gynaecological oncologist can review your CT scans, pathology, and CA-125 results and provide an opinion on treatment plan within 5-7 days.
Ovarian Cancer Awareness Month is a reminder that early diagnosis and optimal treatment save lives. If you or someone you know has received this diagnosis and needs access to the best treatment at a realistic cost, India — and Arodya — are here.
